PCM
ESPR

Prelude Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Prelude Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-34,800
Closed -$57.4K – 1302
2024
Q3 		$57.4K Buy
+34,800
New +$70.3K ﹤0.01% 1205
2015
Q4 		– Sell
-400
Closed -$9K – 1515
2015
Q3 		$9K Buy
+400
New +$25.1K ﹤0.01% 1349

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Prelude Capital Management's ESPR Position: Q2 2026 in Review

Prelude Capital Management increased its Esperion Therapeutics (ESPR) stake by 1,263% in Q2 2026, buying an estimated $554K and bringing the position to 213,636 shares worth $675K. The position accounts for 0.05% of the portfolio, ranked #414.

Prelude Capital Management first reported a position in ESPR in Q2 2017 and has held it in 14 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Prelude Capital Management held 213,636 shares of Esperion Therapeutics worth $675K as of Q2 2026.
  • Prelude Capital Management bought 197,966 Esperion Therapeutics shares in Q2 2026, an estimated $554K.
  • Esperion Therapeutics made up 0.05% of Prelude Capital Management's portfolio in Q2 2026, its #414 holding.
  • Prelude Capital Management first reported a position in Esperion Therapeutics in Q2 2017 and has held it in 14 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.